0001193125-26-213491
SEC filingTango Therapeutics' Board determined on April 10, 2026, that CFO Daniella Beckman would cease serving effective April 15, 2026, with a Separation Agreement executed May 7 providing 12 months severance and accelerated equity vesting.
The departure of Daniella Beckman from her critical roles as CFO and principal officers effective April 15, 2026, follows a board decision announced previously on April 10. The Separation Agreement, effective May 7 with her last employment day May 1, offers substantial retention of talent through generous severance equivalent to one year of base salary, health benefits continuation, and significant equity incentives including 24 months of accelerated vesting and an extended option exercise window to August 31, 2026. These terms, conditioned on a full release of claims, mitigate potential litigation risk while securing her compliance with ongoing confidentiality and nonsolicitation obligations, with noncompete waived.